Zhuang Shougang, Kinsey Gilbert R, Rasbach Kyle, Schnellmann Rick G
Department of Medicine, Brown University School of Medicine, Rhode Island Hospital-Middle House 301, 593 Eddy St., Providence, RI 02903, USA.
Am J Physiol Renal Physiol. 2008 Mar;294(3):F459-68. doi: 10.1152/ajprenal.00473.2007. Epub 2008 Jan 2.
Our recent studies have shown that proliferation of renal proximal tubular cells (RPTC) in the absence of growth factors requires activation of the epidermal growth factor (EGF) receptor. We sought to identify the endogenous EGF receptor ligand and investigate the mechanism(s) by which RPTC proliferate in different models. RPTC expressed both pro- and cleaved forms of heparin-binding epidermal growth factor (HB-EGF) and several metalloproteinases (MMP-2, -3, -9, and ADAM10, ADAM17) that have been reported to cleave HB-EGF. Treatment of RPTC with CRM 197, an inhibitor of HB-EGF binding to the EGF receptor, or downregulation of HB-EGF with small interfering RNA inhibited RPTC proliferation following plating. Furthermore, GM6001 (pan-MMP inhibitor), tumor-necrosis factor protease inhibitor-1 (TAPI-1; MMP and ADAM17 inhibitor), and GW280264X (ADAM10 and -17 inhibitor), but not GI254023X (ADAM10 inhibitor), attenuated the proliferation after plating. Although EGF receptor activation is required for RPTC proliferation after oxidant injury, CRM197, GM6001, and TAPI-1 did not block this response. In contrast, inhibition of Src with PP1 blocked EGF receptor activation and RPTC proliferation after oxidant injury. In addition, PP1 treatment attenuated HB-EGF-enhanced RPTC proliferation. We suggest that RPTC proliferation after plating is mediated by HB-EGF produced through an autocrine/paracrine mechanism and RPTC proliferation following oxidant injury is mediated by Src without involvement of HB-EGF.
我们最近的研究表明,在缺乏生长因子的情况下,肾近端小管细胞(RPTC)的增殖需要表皮生长因子(EGF)受体的激活。我们试图鉴定内源性EGF受体配体,并研究RPTC在不同模型中增殖的机制。RPTC表达肝素结合表皮生长因子(HB-EGF)的前体形式和裂解形式,以及几种据报道可裂解HB-EGF的金属蛋白酶(MMP-2、-3、-9以及ADAM10、ADAM17)。用CRM 197(一种HB-EGF与EGF受体结合的抑制剂)处理RPTC,或用小干扰RNA下调HB-EGF,均可抑制接种后RPTC的增殖。此外,GM6001(泛MMP抑制剂)、肿瘤坏死因子蛋白酶抑制剂-1(TAPI-1;MMP和ADAM17抑制剂)以及GW280264X(ADAM10和-17抑制剂),而非GI254023X(ADAM10抑制剂),可减弱接种后的增殖。尽管氧化损伤后RPTC的增殖需要EGF受体激活,但CRM197、GM6001和TAPI-1并未阻断这种反应。相反,用PP1抑制Src可阻断氧化损伤后EGF受体的激活和RPTC的增殖。此外,PP1处理可减弱HB-EGF增强的RPTC增殖。我们认为,接种后RPTC的增殖是由通过自分泌/旁分泌机制产生的HB-EGF介导的,而氧化损伤后RPTC的增殖是由Src介导的,不涉及HB-EGF。